November 3, 2020 10:21 AM EST
R&D
FDA+

PS: Did any­one at Bio­gen ask the FDA to pull an ad­u­canum­ab con­sci­en­tious ob­jec­tor off their ex­pert pan­el? ‘No com­ment’

John Carroll

Editor & Founder

Yes­ter­day I re­port­ed that Bio­gen had dodged a bul­let when the FDA re­cused long­time Alzheimer’s re­searcher David Knop­man from this week’s ex­pert pan­el re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times